Paragon Therapeutics, Inc.

The latest third quarter data from the National Venture Capital Association (NVCA) and Pitchbook’s Venture Monitor report confirm recent data compiled by Evaluate Pharma, which showed that VC investme

Crescent Biopharma may be behind in the race to introduce a PD-1xVEGF bispecific antibody, but the firm has a clearer path now that it is going public through a reverse merger with GlycoMimetics and

The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the las

Soon-to-be public Oruka Therapeutics will execute a reverse merger with ARCA Biopharma, Inc. and a concurrent $275m financing to help it start clinical development of optimized biologics in psoria